Doggybone™ DNA Technology: A New Breed of Vaccine

Doggybone™ DNA Technology: A New Breed of Vaccine

Doggybone™ DNA (dbDNA) is an innovative technology developed by biotech company Touchlight, with applications in genetic engineering and therapeutics. Plasmids, small circular double-stranded DNA molecules, are the basis of dbDNA. These plasmids can be utilized as vectors in genetic engineering, allowing specific genes to be inserted into bacterial chromosomal DNA and mass-produced to create large quantities of proteins.

The production of dbDNA involves using protelomerase recognition sequences to flank the gene of interest, resulting in a linear plasmid structure. The technology enables cost-effective and rapid scalability, as it can be produced abiotically without the need for bacterial cultures, using rolling circle amplification.

Compared to mRNA vaccines produced using bacterial vectors, dbDNA offers a more cost-effective and scalable method for vaccine production. Pfizer has acquired the right to use dbDNA in manufacturing COVID-19 mRNA vaccines. Studies on dbDNA-based vaccines in animal models have shown promising results, inducing cross-variant neutralizing antibodies and providing protection from viral challenges.

The minimal nature of dbDNA, containing only the functional gene of interest and necessary end groups, may offer advantages in terms of patient safety and minimizing off-target effects. Furthermore, the lack of innate immune recognition towards dbDNA might induce a more controlled immune response desired for a vaccine. Future research will likely explore incorporating dbDNA into vector platforms for clinical application. The cost-effectiveness and potential benefits of dbDNA manufacture make it a promising technology for future vaccine development.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks